References
- Panay N, Ylikorkala O, Archer DF, Rakov V, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120–31
- Somboonporn W, Panna S, Temtanakitpaisan T, Kaewrudee S, Soontrapa S. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011;18:1060–6
- Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 2010;126:483–9
- White WB. Drospirenone with 17β-estradiol in the postmenopausal woman with hypertension. Climacteric 2007;10 (Suppl 1):25–31
- Di Carlo C, Tommaselli GA, Gargano V, Savoia F, Bifulco G, Nappi C. Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric 2010;13:442–6
- Kroft J, Klostermann NR, Moody JRK, Taerk E, Wolfman A. A novel regimen of combination transdermal estrogen and intermittent vaginally administered progesterone for relief of menopausal symptoms. Gynecol Endocrinol 2010;26:902–8
- Sherwin BB, Grigirova M. Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. Fertil Steril 2011;96:399–403
- Canonico M, Scarabin PY. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Climacteric 2009;12(Suppl ):76–80
- Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260–8
- Harvey JA, Pinkerton JV, Pan K, Thompson JR, Mirkin S, Chines AA. The effects of bazedoxifene/conjugated estrogens on breast density in postmenopausal women. Presented at 2011 NAMS Annual Meeting S-1 (Abstract)